0001062993-24-008004.txt : 20240403
0001062993-24-008004.hdr.sgml : 20240403
20240403185001
ACCESSION NUMBER: 0001062993-24-008004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240402
FILED AS OF DATE: 20240403
DATE AS OF CHANGE: 20240403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GILEAD SCIENCES, INC.
CENTRAL INDEX KEY: 0000882095
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40925
FILM NUMBER: 24820775
BUSINESS ADDRESS:
STREET 1: 333 LAKESIDE DR
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
BUSINESS PHONE: 6505743000
MAIL ADDRESS:
STREET 1: 333 LAKESIDE DR
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
FORMER NAME:
FORMER CONFORMED NAME: GILEAD SCIENCES INC
DATE OF NAME CHANGE: 19930328
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xilio Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840233
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 851623397
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 828 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-833-1027
MAIL ADDRESS:
STREET 1: 828 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-04-02
0001840233
Xilio Therapeutics, Inc.
XLO
0000882095
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE
FOSTER CITY
CA
94404
0
0
1
0
0
Common Stock
2024-04-02
4
P
0
485250
0.76
A
7345473
D
Prefunded Warrants (right to buy)
0.0001
2024-04-02
4
P
0
3882450
0.7599
A
Common Stock
3882450
3882450
D
The Prefunded Warrants have no expiration date and are exercisable at any time on or after the date of issuance. A holder of Prefunded Warrants may not exercise the Prefunded Warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.
Gilead Sciences, Inc. By: /s/ Andrew D. Dickson
2024-04-03